AfterRaise/Companies/Circle Pharma

Circle Pharma

$92M Series ERaised yesterdaySouth San Francisco, USABiotech & PharmaUSA
Visit website →

Why now

Where Circle Pharma is today

Circle Pharma announced a Series E round of $92M on 16 September 2026, led by The Column Group.

Latest round
Series E
Amount
$92M
Announced
16 September 2026
Headquarters
South San Francisco, USA
Sector
Biotech & Pharma
Growth stage
Series C+
Investors
The Column Group
Also participating
Nextech Invest, RA Capital Management, Euclidean Capital and Eli Lilly and Company
Relevant leadership
CEO David J. Earp

Momentum AfterRaise intelligence

AfterRaise Score

78
Building momentum
1 funding signal in the last 90 days
Funding recency
40/40
announced within the last 30 days
Round scale
19/25
round size relative to the market
Funding stage
19/20
Series E
Funding cadence
0/15
one funding event tracked this year
Arriving with the signals layer
  • Hiring momentum Open roles and hiring pace
  • Market expansion New offices and new countries
  • Leadership Executive appointments
  • Product activity Launches and releases

In their own words

What Circle Pharma says it is doing

Work here? Reserve your page

Public signal Described in the funding announcement as "biopharmaceutical company developing new targeted macrocycle therapeutics for cancer". Source

Market expansionResearch and development

Public signal Read from the company's own description of what the funding supports.

Since the raise

What has happened since

  • 16 September 2026
    $92M Series E
    Led by The Column Group.

Public signal The timeline currently holds funding events, because those are the signals AfterRaise observes today. Hiring, leadership, expansion and product events join it with the signals layer.

What may happen next

What this raise could create

AfterRaise intelligenceNot a statement of fact

What may happen next

  • New market entry
  • First local hires in the new market
  • Local entity and legal setup
  • Research programme expansion

Opportunities this could create

  • Clinical operations
  • Scientific hiring
  • Licensing and BD partnerships
  • Market-entry advisers
  • Local employment infrastructure

Based on the Biotech & Pharma sector, a Series C+ round and the priorities the company itself set out. Not a statement of fact.

Medium momentum3 connected signals
  • 16 September 2026$92M Series E announced
  • 16 September 2026Stated priority: market expansion
  • 16 September 2026Stated priority: research and development

High momentum means several meaningful company changes have occurred in a short period. Signals here are funding events and the priorities the company stated; hiring, leadership and expansion detection join with the signals layer.

Open to

What Circle Pharma is open to

Not yet specified

Circle Pharma has not told AfterRaise which approaches it welcomes. Until it does, we do not assume. Offers to help are held and shown to the company, and the company decides whether to open a conversation.

Work here? Set your preferences

Opportunities

Ways to work with Circle Pharma

No open opportunities listed

Jobs, projects, partnerships, advisory and supplier needs appear here once the company has claimed its page and published them, and any role we read from its own job board appears automatically.

Work here? Open the first one

Helpful contributors

People who have contributed here

Nobody yet

When someone offers help and the company says it was useful, they appear here. Reputation on AfterRaise is built from contributions the company confirmed, not from follower counts.

Do you work at Circle Pharma?

Reserve your company page.

This page was created from publicly available information. When verified company accounts open, your team will be able to correct your profile, tell the market what you actually need and control how people approach you.

What we do not have yet: the roles and projects you have open. Claiming the page is how you fill those in.

Someone else requesting access does not give them ownership. Every company administrator is verified before access is granted.

The first 1,000 verified funded companies join the Founding 1,000 free for life and keep Founding Company status permanently.

Also moving

Other Biotech & Pharma companies

See the sector